Abivax SA (ABVX) - Net Assets
Based on the latest financial reports, Abivax SA (ABVX) has net assets worth €455.20 Million EUR (≈ $532.18 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€584.34 Million ≈ $683.16 Million USD) and total liabilities (€129.14 Million ≈ $150.97 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible equity quality of Abivax SA to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €455.20 Million |
| % of Total Assets | 77.9% |
| Annual Growth Rate | 24.13% |
| 5-Year Change | 1482.0% |
| 10-Year Change | 702.59% |
| Growth Volatility | 2836.25 |
Abivax SA - Net Assets Trend (2013–2025)
This chart illustrates how Abivax SA's net assets have evolved over time, based on quarterly financial data. See Abivax SA (ABVX) defensive interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Abivax SA (2013–2025)
The table below shows the annual net assets of Abivax SA from 2013 to 2025. For live valuation and market cap data, see ABVX market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €455.20 Million ≈ $532.18 Million |
+1021.64% |
| 2024-12-31 | €40.58 Million ≈ $47.45 Million |
-79.29% |
| 2023-12-31 | €196.01 Million ≈ $229.16 Million |
+10314.98% |
| 2022-12-31 | €1.88 Million ≈ $2.20 Million |
-93.46% |
| 2021-12-31 | €28.77 Million ≈ $33.64 Million |
+515.75% |
| 2020-12-31 | €4.67 Million ≈ $5.46 Million |
-60.33% |
| 2019-12-31 | €11.78 Million ≈ $13.77 Million |
-66.00% |
| 2018-12-31 | €34.65 Million ≈ $40.51 Million |
-28.07% |
| 2017-12-31 | €48.18 Million ≈ $56.33 Million |
-15.05% |
| 2016-12-31 | €56.72 Million ≈ $66.31 Million |
-20.94% |
| 2015-12-31 | €71.74 Million ≈ $83.87 Million |
+111.40% |
| 2014-12-31 | €33.94 Million ≈ $39.67 Million |
-0.25% |
| 2013-12-31 | €34.02 Million ≈ $39.77 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Abivax SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 73848198963.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €785.00K | 0.17% |
| Other Comprehensive Income | €2.31 Million | 0.51% |
| Other Components | €1.19 Billion | 261.55% |
| Total Equity | €455.20 Million | 100.00% |
Abivax SA Competitors by Market Cap
The table below lists competitors of Abivax SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Laurus Labs Limited
NSE:LAURUSLABS
|
$7.99 Billion |
|
Evonik Industries AG
F:EVK
|
$7.99 Billion |
|
BlueFocus Communication Group
SHE:300058
|
$8.01 Billion |
|
Trade Desk Inc
NASDAQ:TTD
|
$8.01 Billion |
|
FactSet Research Systems Inc
NYSE:FDS
|
$7.99 Billion |
|
Full Truck Alliance Co Ltd ADR
NYSE:YMM
|
$7.98 Billion |
|
Simpson Manufacturing Company Inc
NYSE:SSD
|
$7.97 Billion |
|
Columbia Banking System Inc
NASDAQ:COLB
|
$7.97 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Abivax SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 40,584,000 to 455,205,000, a change of 414,621,000 (1021.6%).
- Net loss of 336,102,000 reduced equity.
- New share issuances of 648,124,000 increased equity.
- Other comprehensive income increased equity by 2,384,000.
- Other factors increased equity by 100,215,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-336.10 Million | -73.84% |
| Share Issuances | €648.12 Million | +142.38% |
| Other Comprehensive Income | €2.38 Million | +0.52% |
| Other Changes | €100.22 Million | +22.02% |
| Total Change | €- | 1021.64% |
Book Value vs Market Value Analysis
This analysis compares Abivax SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 13.17x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 23.49x to 13.17x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | €3.67 | €86.20 | x |
| 2014-12-31 | €4.91 | €86.20 | x |
| 2015-12-31 | €7.37 | €86.20 | x |
| 2016-12-31 | €5.83 | €86.20 | x |
| 2017-12-31 | €4.85 | €86.20 | x |
| 2018-12-31 | €3.39 | €86.20 | x |
| 2019-12-31 | €0.97 | €86.20 | x |
| 2020-12-31 | €0.33 | €86.20 | x |
| 2021-12-31 | €1.72 | €86.20 | x |
| 2022-12-31 | €0.38 | €86.20 | x |
| 2023-12-31 | €4.55 | €86.20 | x |
| 2024-12-31 | €0.64 | €86.20 | x |
| 2025-12-31 | €6.55 | €86.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Abivax SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -73.84%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.28x
- Recent ROE (-73.84%) is above the historical average (-214.48%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -17.32% | -7871.50% | 0.00x | 1.13x | €-9.30 Million |
| 2014 | -14.97% | -7566.96% | 0.00x | 1.12x | €-8.47 Million |
| 2015 | -22.24% | -6997.81% | 0.00x | 1.06x | €-23.13 Million |
| 2016 | -25.23% | -9475.50% | 0.00x | 1.07x | €-19.98 Million |
| 2017 | -23.29% | -3152.25% | 0.01x | 1.12x | €-16.04 Million |
| 2018 | -45.66% | -1941.47% | 0.02x | 1.56x | €-19.29 Million |
| 2019 | -260.03% | 0.00% | 0.00x | 4.39x | €-31.81 Million |
| 2020 | -803.57% | -268221.43% | 0.00x | 15.26x | €-38.02 Million |
| 2021 | -147.54% | -114735.14% | 0.00x | 3.84x | €-45.33 Million |
| 2022 | -844.90% | -1325.33% | 0.06x | 10.20x | €-61.46 Million |
| 2023 | -75.37% | -3197.14% | 0.01x | 1.67x | €-167.34 Million |
| 2024 | -434.26% | -1633.08% | 0.05x | 5.06x | €-180.30 Million |
| 2025 | -73.84% | 0.00% | 0.00x | 1.28x | €-381.62 Million |
Industry Comparison
This section compares Abivax SA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $17,856,389
- Average return on equity (ROE) among peers: -51.01%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Abivax SA (ABVX) | €455.20 Million | -17.32% | 0.28x | $7.99 Billion |
| Abionyx Pharma SA (ABNX) | $33.20 Million | -50.12% | 0.39x | $92.39 Million |
| Adocia (ADOC) | $47.05 Million | 26.68% | 0.87x | $93.64 Million |
| Aelis Farma SA (AELIS) | $898.00K | 63.92% | 30.53x | $16.96 Million |
| Biophytis S.A. (ALBPS) | $4.52 Million | -176.01% | 0.86x | $752.91K |
| Cellectis (ALCLS) | $84.69 Million | -119.32% | 2.95x | $228.80 Million |
| Advicenne (ALDVI) | $-10.62 Million | 0.00% | 0.00x | $18.58 Million |
| Genoway (ALGEN) | $1.90 Million | 0.00% | 1.85x | $31.09 Million |
| Integragen (ALINT) | $1.48 Million | -204.25% | 1.41x | $1.00 Million |
| Medesis Pharma SA (ALMDP) | $-2.42 Million | 0.00% | 0.00x | $1.80 Million |
About Abivax SA
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials f… Read more